Table 4.
The KEGG pathways by the DAVID database for the target list of UA derived from molecular docking calculations
| Category | Term | Count | % | P-value | Genes | Fold enrichment | Benjamini | FDR |
|---|---|---|---|---|---|---|---|---|
| KEGG pathway | Pathways in cancer | 58 | 12.42 | 4.97E-12 | HSP90AB1, HRAS, PPARD, MMP-9, PPARG, PTEN, MMP-1, AKT1, CDC42, CASP3, CASP8, RARB, AKT2, PRKCA, EGFR, PIK3CG, AR, RET, HSP90AA1, BRAF, RXRA, TP53, CDK6, RB1, CDK2, PRKCB, MAPK1, MAPK3, MDM2, MAPK9, MAPK8, GSTP1, FGFR2, TRAF2, FGFR1, XIAP, GRB2, ERBB2, BCL2L1, KIT, ARNT, IGF1R, PTK2, BCL2, RAC1, TRAF6, CSF1R, EPAS1, MAP2K1, TGFBR1, MET, RAF1, IGF1, MAPK10, HDAC2, GSK3B, JAK1, ABL1 | 2.64 | 7.75E-10 | 5.97E-09 |
| KEGG pathway | Prostate cancer | 28 | 6.00 | 7.42E-12 | FGFR2, HSP90AB1, FGFR1, HRAS, GRB2, ERBB2, PTEN, AKT1, IGF1R, PDPK1, BCL2, AKT2, EGFR, PIK3CG, AR, HSP90AA1, BRAF, MAP2K1, TP53, IGF1, RAF1, RB1, CDK2, MAPK1, GSK3B, MAPK3, MDM2, GSTP1 | 4.69 | 5.79E-10 | 8.92E-09 |
| KEGG pathway | Non-small-cell lung cancer | 20 | 4.28 | 6.18E-10 | PRKCA, EGFR, PIK3CG, HRAS, MAP2K1, BRAF, GRB2, RXRA, ERBB2, TP53, RAF1, CDK6, RB1, PRKCB, AKT1, MAPK1, PDPK1, MAPK3, RARB, AKT2 | 5.52 | 3.21E-08 | 7.43E-07 |
| KEGG pathway | ERBB signaling pathway | 25 | 5.35 | 1.01E-09 | HRAS, ERBB4, GRB2, ERBB2, SRC, AKT1, PTK2, PAK4, PAK1, AKT2, PRKCA, EGFR, PIK3CG, BRAF, MAP2K1, RAF1, MAPK10, PRKCB, NCK2, MAPK1, GSK3B, MAPK3, MAPK9, MAPK8, ABL1 | 4.29 | 3.95E-08 | 1.22E-06 |
| KEGG pathway | Fc epsilon RI signaling pathway | 23 | 4.93 | 3.27E-09 | PRKCA, PIK3CG, PDK1, HRAS, MAP2K1, LYN, GRB2, RAF1, MAPK10, PRKCB, BTK, AKT1, MAPK1, GAB2, FYN, MAPK14, MAPK3, RAC1, PLA2G2A, MAPK9, MAPK8, AKT2, SYK | 4.40 | 1.02E-07 | 3.93E-06 |
| KEGG pathway | Glioma | 20 | 4.28 | 1.18E-08 | PRKCA, EGFR, PIK3CG, HRAS, MAP2K1, BRAF, GRB2, TP53, IGF1, RAF1, CDK6, RB1, PTEN, PRKCB, AKT1, MAPK1, IGF1R, MAPK3, MDM2, AKT2 | 4.73 | 3.07E-07 | 1.42E-05 |
| KEGG pathway | Pancreatic cancer | 21 | 4.50 | 2.31E-08 | EGFR, PIK3CG, MAP2K1, BRAF, ERBB2, TGFBR1, TP53, RAF1, CDK6, RB1, BCL2L1, MAPK10, AKT1, CDC42, MAPK1, MAPK3, RAC1, MAPK9, JAK1, MAPK8, AKT2 | 4.35 | 5.16E-07 | 2.78E-05 |
| KEGG pathway | Progesterone-mediated oocyte maturation | 23 | 4.93 | 2.38E-08 | HSP90AB1, PIK3CG, HSP90AA1, MAP2K1, BRAF, GNAI1, IGF1, RAF1, PDE3B, MAPK10, CDK2, AKT1, PGR, MAPK1, IGF1R, RPS6KA1, PLK1, MAPK14, MAPK3, MAPK9, MAPK8, PRKACA, AKT2 | 3.99 | 4.65E-07 | 2.87E-05 |
| KEGG pathway | Drug metabolism | 19 | 4.07 | 5.60E-08 | GSTA1, GSTA2, GSTA3, GSTA4, MAOA, MAOB, ADH5, ADH1C, ADH1B, GSTT1, ADH1A, ADH7, ALDH3A1, GSTM1, GSTM2, ADH4, GSTK1, GSTZ1, GSTO2, GSTO1, GSTP1 | 4.57 | 9.71E-07 | 6.73E-05 |
| KEGG pathway | Focal adhesion | 36 | 7.71 | 9.22E-08 | HRAS, XIAP, GRB2, ERBB2, PTEN, SRC, AKT1, CDC42, IGF1R, PDPK1, PTK2, PAK4, BCL2, RAC1, PAK1, AKT2, EGFR, PIK3CG, PRKCA, MAP2K1, ROCK1, BRAF, MET, IGF1, RAF1, MAPK10, PPP1CC, PRKCB, KDR, MAPK1, PPP1CA, FYN, GSK3B, MAPK3, MAPK9, MAPK8 | 2.67 | 1.44E-06 | 1.11E-04 |
| KEGG pathway | Neurotrophin signaling pathway | 27 | 5.78 | 1.05E-07 | HRAS, YWHAZ, GRB2, MAPKAPK2, IRAK4, AKT1, CDC42, BCL2, RAC1, TRAF6, AKT2, PDK1, PIK3CG, BRAF, MAP2K1, TP53, RAF1, MAPK10, PTPN11, MAPK1, RPS6KA1, MAPK14, GSK3B, MAPK3, MAPK9, MAPK8, ABL1 | 3.25 | 1.49E-06 | 1.26E-04 |
| KEGG pathway | Insulin signaling pathway | 28 | 6.00 | 1.66E-07 | HRAS, GRB2, PDE3B, AKT1, PDPK1, PRKACA, INSR, AKT2, PIK3CG, MAP2K1, BRAF, PRKCI, FBP1, RAF1, ACACB, MAPK10, PPP1CC, PPARGC1A, PCK1, MAPK1, PPP1CA, EIF4E, PYGL, GSK3B, MAPK3, MAPK9, MAPK8, PTPN1 | 3.09 | 2.16E-06 | 1.99E-04 |
| KEGG pathway | Chronic myeloid leukemia | 20 | 4.28 | 2.62E-07 | PIK3CG, HRAS, BRAF, MAP2K1, GRB2, TGFBR1, TP53, RAF1, CDK6, RB1, BCL2L1, PTPN11, AKT1, MAPK1, HDAC2, GAB2, MAPK3, MDM2, ABL1, AKT2 | 3.98 | 3.14E-06 | 3.15E-04 |
| KEGG pathway | Colorectal cancer | 21 | 4.50 | 3.78E-07 | EGFR, PIK3CG, MAP2K1, BRAF, GRB2, TGFBR1, MET, TP53, RAF1, MAPK10, AKT1, MAPK1, IGF1R, CASP3, GSK3B, BCL2, MAPK3, RAC1, MAPK9, MAPK8, AKT2 | 3.73 | 4.21E-06 | 4.54E-04 |
| KEGG pathway | T-cell receptor signaling pathway | 24 | 5.14 | 4.36E-07 | PIK3CG, PDK1, ITK, HRAS, MAP2K1, GRB2, RAF1, AKT1, CDC42, MAPK1, NCK2, PRKCQ, FYN, MAPK14, GSK3B, PAK4, LCK, MAPK3, ZAP70, MAPK9, PAK1, IL2, AKT2, DLG1 | 3.31 | 4.54E-06 | 5.24E-04 |
| KEGG pathway | Melanoma | 19 | 4.07 | 5.39E-07 | EGFR, PIK3CG, FGFR1, HRAS, MAP2K1, BRAF, MET, TP53, IGF1, RAF1, CDK6, RB1, PTEN, AKT1, MAPK1, IGF1R, MAPK3, MDM2, AKT2 | 3.99 | 5.25E-06 | 6.48E-04 |
| KEGG pathway | Endometrial cancer | 16 | 3.43 | 8.09E-07 | EGFR, PIK3CG, HRAS, BRAF, MAP2K1, GRB2, ERBB2, TP53, RAF1, PTEN, AKT1, MAPK1, PDPK1, GSK3B, MAPK3, AKT2 | 4.59 | 7.42E-06 | 9.72E-04 |
| KEGG pathway | Metabolism of xenobiotics by cytochrome P450 | 17 | 3.64 | 1.12E-06 | GSTA1, GSTA2, GSTA3, GSTA4, ADH5, ADH1C, ADH1B, GSTT1, ADH1A, ADH7, ALDH3A1, GSTM1, GSTM2, ADH4, GSTK1, GSTZ1, GSTO2, GSTO1, GSTP1 | 4.23 | 9.69E-06 | 0.001345 |
| KEGG pathway | VEGF signaling pathway | 19 | 4.07 | 1.29E-06 | PRKCA, PIK3CG, HRAS, MAP2K1, MAPKAPK3, RAF1, MAPKAPK2, SRC, KDR, PRKCB, AKT1, CDC42, MAPK1, PTK2, MAPK14, MAPK3, RAC1, PLA2G2A, AKT2 | 3.78 | 1.06E-05 | 0.001555 |
| KEGG pathway | Bladder cancer | 14 | 3.00 | 1.84E-06 | EGFR, HRAS, BRAF, MAP2K1, ERBB2, MMP-9, TP53, RAF1, RB1, MMP-1, MAPK1, TYMP, MAPK3, MDM2 | 4.97 | 1.43E-05 | 0.00221 |
| KEGG pathway | Adherens junction | 19 | 4.07 | 1.95E-06 | EGFR, PTPRB, FGFR1, ERBB2, TGFBR1, MET, SRC, CSNK2A2, CDC42, MAPK1, IGF1R, TJP1, CSNK2A1, FYN, MAPK3, RAC1, PTPN1, INSR, MLLT4 | 3.68 | 1.45E-05 | 0.002349 |
| KEGG pathway | Renal cell carcinoma | 18 | 3.85 | 2.15E-06 | PIK3CG, HRAS, MAP2K1, BRAF, EPAS1, GRB2, MET, RAF1, ARNT, PTPN11, AKT1, CDC42, MAPK1, PAK4, MAPK3, RAC1, PAK1, AKT2 | 3.83 | 1.52E-05 | 0.002583 |
| KEGG pathway | Natural killer cell- mediated cytotoxicity | 25 | 5.35 | 5.63E-06 | ITGAL, HRAS, GRB2, CASP3, PTK2B, RAC1, ZAP70, PAK1, SYK, PRKCA, PIK3CG, BRAF, MAP2K1, HLA-A, RAF1, GZMB, HLA-B, HLA-E, HLA-G, PTPN11, PRKCB, MAPK1, FYN, LCK, MAPK3 | 2.80 | 3.82E-05 | 0.006771 |
| KEGG pathway | Chemokine signaling pathway | 30 | 6.42 | 1.36E-05 | HRAS, GRB2, GNAI1, ADRBK1, AKT1, CDC42, PTK2, CXCR4, TIAM1, PTK2B, RAC1, PRKACA, GNG2, PAK1, AKT2, PIK3CG, ITK, MAP2K1, ROCK1, BRAF, LYN, HCK, RAF1, PRKCB, MAPK1, GNB1, GSK3B, MAPK3, GRK6, JAK3 | 2.39 | 8.82E-05 | 0.016317 |
| KEGG pathway | Glutathione metabolism | 14 | 3.00 | 1.57E-05 | GSTA1, GSTA2, ODC1, GSTA3, GSTA4, GSTT1, GSTM1, GSTM2, G6PD, GSTK1, GSTZ1, GSTO2, GSTO1, GSTP1 | 4.18 | 9.77E-05 | 0.018816 |
| KEGG pathway | Complement and coagulation cascades | 16 | 3.43 | 3.59E-05 | PLAT, F11, F10, F8, F9, F7, C1QC, PLG, C1QA, C1QB, SERPINE1, F2, SERPINC1, CFD, CPB2, PLAU | 3.46 | 2.15E-04 | 0.043123 |
| KEGG pathway | B-cell receptor signaling pathway | 16 | 3.43 | 9.98E-05 | PIK3CG, HRAS, LYN, MAP2K1, GRB2, RAF1, PRKCB, BTK, AKT1, MAPK1, DAPP1, GSK3B, MAPK3, RAC1, AKT2, SYK | 3.18 | 5.76E-04 | 0.119869 |
| KEGG pathway | Adipocytokine signaling pathway | 15 | 3.21 | 1.03E-04 | TRAF2, PPARA, CHKB, RXRA, ACACB, MAPK10, PPARGC1A, PCK1, PTPN11, AKT1, PRKCQ, TNFRSF1A, MAPK9, MAPK8, AKT2 | 3.34 | 5.76E-04 | 0.124225 |
| KEGG pathway | Epithelial cell signaling in Helicobacter pylori infection | 15 | 3.21 | 1.22E-04 | EGFR, LYN, MET, MAPK10, SRC, PTPN11, CDC42, TJP1, CASP3, MAPK14, RAC1, ADAM17, MAPK9, MAPK8, PAK1 | 3.29 | 6.59E-04 | 0.147114 |
| KEGG pathway | Long-term depression | 15 | 3.21 | 1.44E-04 | PRKCA, PPP2R1A, HRAS, BRAF, LYN, MAP2K1, GNAI1, IGF1, RAF1, PRKCB, IGF1R, MAPK1, PPP2CA, MAPK3, PLA2G2A | 3.24 | 7.51E-04 | 0.173569 |
| KEGG pathway | Endocytosis | 27 | 5.78 | 1.89E-04 | FGFR2, HRAS, ERBB4, TSG101, ADRBK1, EEA1, KIT, SRC, IGF1R, CDC42, CXCR4, TRAF6, CSF1R, EGFR, RET, TGFBR1, MET, PRKCI, HLA-A, HLA-B, HLA-E, HLA-G, KDR, GRK6, HGS, MDM2, PDCD6IP | 2.19 | 9.52E-04 | 0.227192 |
| KEGG pathway | GnRH signaling pathway | 18 | 3.85 | 2.21E-04 | PRKCA, EGFR, HRAS, MAP2K1, GRB2, RAF1, MAPK10, SRC, PRKCB, CDC42, MAPK1, PTK2B, MAPK14, MAPK3, PLA2G2A, MAPK9, PRKACA, MAPK8 | 2.74 | 0.0010769 | 0.265376 |
| KEGG pathway | Acute myeloid leukemia | 13 | 2.78 | 3.55E-04 | PIK3CG, PPARD, HRAS, BRAF, MAP2K1, GRB2, PIM1, RAF1, KIT, AKT1, MAPK1, MAPK3, AKT2 | 3.34 | 0.0016786 | 0.426361 |
| KEGG pathway | Small-cell lung cancer | 16 | 3.43 | 3.73E-04 | PIK3CG, TRAF2, XIAP, RXRA, TP53, CDK6, RB1, BCL2L1, PTEN, CDK2, AKT1, PTK2, BCL2, RARB, TRAF6, AKT2 | 2.84 | 0.0017096 | 0.44736 |
| KEGG pathway | Thyroid cancer | 9 | 1.93 | 4.55E-04 | MAPK1, HRAS, RET, MAP2K1, BRAF, RXRA, MAPK3, PPARG, TP53 | 4.63 | 0.0020265 | 0.545693 |
| KEGG pathway | Glycolysis/gluconeogenesis | 13 | 2.78 | 4.94E-04 | ADH5, FBP1, ADH1C, ADH1B, ADH1A, ADH7, DLAT, PDHB, PCK1, ALDH3A1, ALDH7A1, TPI1, ADH4, ALDH2, PDHA1 | 3.23 | 0.0021381 | 0.592084 |
| KEGG pathway | Tyrosine metabolism | 11 | 2.36 | 5.00E-04 | PNMT, MAOA, MAOB, ADH5, ADH1C, ADH1B, ADH1A, ADH7, COMT, ALDH3A1, MIF, ADH4, GSTZ1 | 3.73 | 0.0021056 | 0.599243 |
| KEGG pathway | NOD-like receptor signaling pathway | 13 | 2.78 | 6.75E-04 | HSP90AB1, HSP90AA1, XIAP, MAPK10, MAPK1, ERBB2IP, MAPK14, MAPK3, CASP8, MAPK9, MAPK8, CASP1, TRAF6 | 3.13 | 0.002769 | 0.808763 |
| KEGG pathway | MAPK signaling pathway | 33 | 7.07 | 7.57E-04 | FGFR2, TRAF2, FGFR1, HRAS, GRB2, MAPKAPK3, MAPKAPK2, AKT1, CDC42, TNFRSF1A, CASP3, RAC1, PRKACA, PAK1, TRAF6, AKT2, EGFR, PRKCA, MAP2K1, BRAF, TGFBR1, TP53, RAF1, MAPK10, PRKCB, MAPK1, DUSP3, RPS6KA1, MAPK14, MAPK3, PLA2G2A, MAPK9, MAPK8 | 1.84 | 0.0030264 | 0.906871 |
| KEGG pathway | Aldosterone-regulated sodium reabsorption | 10 | 2.14 | 0.001243 | PRKCA, PIK3CG, MAPK1, PDPK1, SGK1, MAPK3, IGF1, SFN, INSR, PRKCB | 3.64 | 0.0048377 | 1.483839 |
| KEGG pathway | Fcγ R-mediated phagocytosis | 16 | 3.43 | 0.001417 | PRKCA, PIK3CG, LYN, MAP2K1, HCK, RAF1, PRKCB, AKT1, CDC42, MAPK1, GAB2, MAPK3, RAC1, PAK1, AKT2, SYK | 2.51 | 0.0053789 | 1.689783 |
| KEGG pathway | p53 signaling pathway | 13 | 2.78 | 0.001583 | TP53, IGF1, CHEK1, CDK6, CHEK2, SFN, PTEN, CDK2, CASP3, CASP8, SERPINE1, MDM2, MDM4 | 2.85 | 0.0058663 | 1.886424 |
| KEGG pathway | Prion diseases | 9 | 1.93 | 0.001753 | C1QA, C1QB, MAPK1, MAP2K1, FYN, MAPK3, STIP1, PRKACA, C1QC | 3.83 | 0.0063436 | 2.086826 |
| KEGG pathway | Axon guidance | 19 | 4.07 | 0.002119 | HRAS, NRP1, ROCK1, GNAI1, MET, EPHB4, CDK5, CDC42, NCK2, MAPK1, PTK2, CXCR4, FYN, GSK3B, PAK4, MAPK3, RAC1, PAK1, ABL1 | 2.20 | 0.0074937 | 2.51844 |
| KEGG pathway | Oocyte meiosis | 17 | 3.64 | 0.002402 | PPP2R1A, YWHAZ, AR, MAP2K1, IGF1, AURKA, PPP1CC, CDK2, PGR, MAPK1, IGF1R, PPP1CA, RPS6KA1, PLK1, PPP2CA, MAPK3, PRKACA | 2.30 | 0.0083009 | 2.849446 |
| KEGG pathway | Pyruvate metabolism | 9 | 1.93 | 0.004272 | ALDH7A1, ME2, ALDH2, GLO1, PDHA1, DLAT, ACACB, PDHB, PCK1 | 3.36 | 0.0144151 | 5.017313 |
| KEGG pathway | Apoptosis | 14 | 3.00 | 0.00474 | PIK3CG, TRAF2, XIAP, TP53, BCL2L1, AKT1, IRAK4, TNFRSF1A, CASP3, CASP7, BCL2, CASP8, PRKACA, AKT2 | 2.40 | 0.0156455 | 5.551863 |
| KEGG pathway | Leukocyte transendothelial migration | 17 | 3.64 | 0.004911 | PRKCA, PIK3CG, ITK, ITGAL, ROCK1, GNAI1, NCF4, MMP-9, PTPN11, PRKCB, CDC42, PTK2, PTK2B, CXCR4, MAPK14, RAC1, MLLT4 | 2.15 | 0.0158742 | 5.747625 |
| KEGG pathway | Long-term potentiation | 12 | 2.57 | 0.00495 | PRKCA, MAPK1, PPP1CA, HRAS, RPS6KA1, MAP2K1, BRAF, MAPK3, RAF1, PRKACA, PPP1CC, PRKCB | 2.63 | 0.0156745 | 5.791613 |
| KEGG pathway | PPAR signaling pathway | 12 | 2.57 | 0.005547 | PPARA, PDPK1, PPARD, CHKB, RXRA, PPARG, FABP3, FABP4, FABP7, MMP-1, PCK1, NR1H3 | 2.59 | 0.0172046 | 6.46863 |
| KEGG pathway | Gap junction | 14 | 3.00 | 0.005771 | PRKCA, EGFR, HRAS, MAP2K1, GRB2, GNAI1, GJA1, RAF1, SRC, PRKCB, MAPK1, TJP1, MAPK3, PRKACA | 2.35 | 0.0175475 | 6.721689 |
| KEGG pathway | Drug metabolism | 9 | 1.93 | 0.006762 | XDH, TYMP, UMPS, CES1, NAT1, NAT2, CDA, HPRT1, TPMT | 3.12 | 0.0201485 | 7.833234 |
| KEGG pathway | mTOR signaling pathway | 10 | 2.14 | 0.006809 | PIK3CG, AKT1, MAPK1, PDPK1, EIF4E, RPS6KA1, BRAF, MAPK3, IGF1, AKT2 | 2.87 | 0.0199102 | 7.886251 |
| KEGG pathway | Toll-like receptor signaling pathway | 15 | 3.21 | 0.006813 | PIK3CG, MAP2K1, CD40, MAPK10, AKT1, IRAK4, MAPK1, MAPK14, MAPK3, RAC1, CASP8, MAPK9, MAPK8, TRAF6, AKT2 | 2.21 | 0.0195569 | 7.890864 |
| KEGG pathway | Viral myocarditis | 12 | 2.57 | 0.00691 | EIF4G1, ITGAL, CASP3, FYN, CASP8, RAC1, HLA-A, HLA-B, CD40, HLA-E, ABL1, HLA-G | 2.52 | 0.0194747 | 7.998282 |
| KEGG pathway | Vascular smooth muscle contraction | 16 | 3.43 | 0.007143 | PRKCA, BRAF, MAP2K1, ROCK1, ADORA2A, RAF1, PPP1CC, PRKCB, PRKCQ, MAPK1, PPP1CA, MAPK3, PLA2G2A, PRKACA, CALCRL, RAMP1 | 2.13 | 0.019771 | 8.257365 |
| KEGG pathway | Primary immunodeficiency | 8 | 1.71 | 0.007398 | UNG, LCK, TAP1, ZAP70, AIRE, JAK3, CD40, BTK | 3.41 | 0.020118 | 8.540799 |
| KEGG pathway | Arginine and proline metabolism | 10 | 2.14 | 0.007733 | ODC1, ARG1, ALDH7A1, GATM, MAOA, ARG2, MAOB, ALDH2, GAMT, AMD1 | 2.81 | 0.0206644 | 8.91132 |
| KEGG pathway | Histidine metabolism | 7 | 1.50 | 0.010917 | ASPA, ALDH7A1, HNMT, MAOA, MAOB, ALDH2, ALDH3A1 | 3.60 | 0.028606 | 12.36319 |
| KEGG pathway | Purine metabolism | 19 | 4.07 | 0.01285 | XDH, NUDT2, DCK, PDE3B, PDE4D, HPRT1, PNP, GART, NME2, PDE2A, ATIC, NME1, NT5M, PDE7A, PDE4A, ADK, PDE4B, PDE5A, PDE9A, PDE8A | 1.85 | 0.0330669 | 14.40039 |
| KEGG pathway | Tight junction | 17 | 3.64 | 0.01618 | PRKCA, PPP2R1A, HRAS, GNAI1, PRKCI, PTEN, SRC, PRKCB, AKT1, CSNK2A2, CDC42, PRKCQ, TJP1, CSNK2A1, PPP2CA, MLLT4, AKT2 | 1.89 | 0.0408596 | 17.80881 |
| KEGG pathway | Renin–angiotensin system | 5 | 1.07 | 0.023312 | ACE, REN, MME, CMA1, CTSG | 4.39 | 0.0576238 | 24.69256 |
| KEGG pathway | Allograft rejection | 7 | 1.50 | 0.030239 | HLA-A, GZMB, HLA-B, CD40, HLA-E, HLA-G, IL2 | 2.90 | 0.0732134 | 30.86838 |
| KEGG pathway | Cell cycle | 15 | 3.21 | 0.038296 | YWHAZ, TP53, TTK, CDK6, CHEK1, RB1, CHEK2, SFN, WEE1, CDK2, HDAC2, PLK1, GSK3B, MDM2, ABL1 | 1.79 | 0.090792 | 37.46662 |
| KEGG pathway | Sulfur metabolism | 4 | 0.86 | 0.041478 | SULT1A1, SULT2B1, SULT1A2, SULT1E1 | 4.97 | 0.0966722 | 39.90887 |
| KEGG pathway | Fatty acid metabolism | 7 | 1.50 | 0.04772 | ALDH7A1, ADH4, CHKB, ADH1C, ALDH2, ADH5, ADH1B, ADH7, ADH1A | 2.61 | 0.1091442 | 44.44857 |
| KEGG pathway | Glycine, serine, and threonine metabolism | 6 | 1.28 | 0.052437 | GATM, MAOA, MAOB, GAMT, GNMT, AGXT | 2.89 | 0.117864 | 47.66781 |
| KEGG pathway | ALS | 8 | 1.71 | 0.060969 | TNFRSF1A, CASP3, MAPK14, BCL2, RAC1, TP53, BCL2L1, CASP1 | 2.25 | 0.1343859 | 53.06039 |
| KEGG pathway | Nicotinate and nicotinamide metabolism | 5 | 1.07 | 0.072217 | NAMPT, CD38, NT5M, PNP, NNMT | 3.11 | 0.155886 | 59.39099 |
| KEGG pathway | Caffeine metabolism | 3 | 0.64 | 0.074832 | XDH, NAT1, NAT2 | 6.39 | 0.1591473 | 60.74629 |
| KEGG pathway | Alzheimer’s disease | 17 | 3.64 | 0.076679 | HSD17B10, CDK5R1, IDE, MME, CDK5, NAE1, MAPK1, TNFRSF1A, APP, CASP3, BACE2, GSK3B, CASP7, MAPK3, CASP8, BACE1, ADAM17 | 1.56 | 0.1607853 | 61.67824 |
| KEGG pathway | Wnt signaling pathway | 16 | 3.43 | 0.078172 | PRKCA, PPP2R1A, PPARD, ROCK1, MMP-7, TP53, MAPK10, PRKCB, CSNK2A2, CSNK2A1, PPP2CA, GSK3B, RAC1, MAPK9, PRKACA, MAPK8 | 1.58 | 0.1616832 | 62.41638 |
| KEGG pathway | Regulation of actin cytoskeleton | 21 | 4.50 | 0.080954 | EGFR, FGFR2, PIK3CG, FGFR1, ITGAL, HRAS, ROCK1, BRAF, MAP2K1, RAF1, PPP1CC, CDC42, MAPK1, PPP1CA, PTK2, TIAM1, PAK4, F2, MAPK3, RAC1, PAK1 | 1.46 | 0.1650651 | 63.75741 |
| KEGG pathway | Dorso–ventral axis formation | 5 | 1.07 | 0.081647 | EGFR, MAPK1, MAP2K1, GRB2, MAPK3 | 2.98 | 0.164358 | 64.08485 |
| KEGG pathway | One carbon pool by folate | 4 | 0.86 | 0.086763 | TYMS, DHFR, ATIC, GART | 3.73 | 0.172031 | 66.4176 |
| KEGG pathway | Type II diabetes mellitus | 7 | 1.50 | 0.090845 | PIK3CG, MAPK1, MAPK3, MAPK9, MAPK8, MAPK10, INSR | 2.22 | 0.1775696 | 68.17856 |
Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; DAVID, Database for Annotation, Visualization, and Integrated Discovery; UA, ursolic acid; FDR, false discovery rate; ALS, amyotrophic lateral sclerosis. it shows that UA exerts an ameliorating effect on DMN-induced liver fibrosis in rats through reducing the accumulation of collagen and suppressing the expression of α-SMA in rat HSCs.